Balyasny Asset Management
PTCT icon

Balyasny Asset Management’s PTC Therapeutics PTCT Stock Holding History

Balyasny Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-200,000
Closed -$6.75M – 1968
2018
Q2 		$6.75M Buy
+200,000
New +$6.24M 0.03% 595
2016
Q4 		– Sell
-96,274
Closed -$238K – 1458
2016
Q3 		$238K Buy
+96,274
New +$783K ﹤0.01% 852
2015
Q2 		– Sell
-57,000
Closed -$3.47M – 1286
2015
Q1 		$3.47M Buy
+57,000
New +$3.48M 0.03% 539

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Balyasny Asset Management's PTCT Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in PTC Therapeutics (PTCT) in Q1 2026: 460,564 shares worth $31.4M. The stake represents 0.04% of the portfolio and ranks #507 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in PTCT as recently as Q3 2025.

Balyasny Asset Management first reported a position in PTCT in Q2 2014 and has held it in 22 quarters since. The position peaked at $32.9M in Q3 2018. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Balyasny Asset Management held 460,564 shares of PTC Therapeutics worth $31.4M as of Q1 2026.
  • PTC Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • PTC Therapeutics made up 0.04% of Balyasny Asset Management's portfolio in Q1 2026, its #507 holding.
  • Balyasny Asset Management first reported a position in PTC Therapeutics in Q2 2014 and has held it in 22 quarters since.
  • Balyasny Asset Management's PTC Therapeutics position peaked at $32.9M in Q3 2018.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.